China deal..... Fukang Ren?, page-11

Valid concerns bread. I appreciate the opposing view, it’s healthy. Thanks for bringing it up.

My take on my limited knowledge of the Chinese company:
1. It won’t take long to determine whether the partner is the real deal or otherwise. Im sure Maria will use the US launch as a baseline
2. Maria has added take-or pay (minimum order requirements) so we’re going to see sales regardless
3. Maria has demonstrated experience dealing with poor performing partners (e.g sacking Ikon for purported poor evolis marketing, refinancing the R&D loan facility because of unfavourable terms). She isn’t afraid of making hard decisions
4. The board is experienced.
I pressume Bruce Gordon has experience dealing with the Chinese via PKF https://www.pkf.com.au/search/?query=China
Finton Walton is associated with Pharmaventures who also have experience in China http://www.pharmaventures.com/search/node/China
Martin Cross was global head of marketing for Novartis at one point and pressume this would have included China
5. There is little risk for Cellmid. We focus on the US and pass on all the marketing/sales risk to this third party